Results for tag: "Osteopenia Drug"

The Osteopenia Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. Osteopenia is a condition characterized by low bone mineral density, which can lead to an increased risk of fractures. Treatment for osteopenia typically involves medications that help to increase bone mineral density, such as bisphosphonates, calcitonin, and selective estrogen receptor modulators (SERMs). These drugs are used to reduce the risk of fractures and to slow the progression of the disease. The Osteopenia Drug market is highly competitive, with a number of large pharmaceutical companies offering products. These companies include Amgen, Merck, Novartis, Pfizer, and Eli Lilly. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more